The estimated Net Worth of Johan Christenson is at least $12.3 million dollars as of 30 June 2020. Johan Christenson owns over 240,000 units of Aprea Therapeutics stock worth over $12,259,335 and over the last 5 years he sold APRE stock worth over $0. In addition, he makes $10,000 as Independent Director at Aprea Therapeutics.
Sign up
Johan Christenson APRE stock SEC Form 4 insiders trading
Johan has made over 2 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 240,000 units of APRE stock worth $4,080,000 on 30 June 2020.
The largest trade he's ever made was buying 266,667 units of Aprea Therapeutics stock on 7 October 2019 worth over $4,000,005. On average, Johan trades about 126,667 units every 67 days since 2019. As of 30 June 2020 he still owns at least 3,807,247 units of Aprea Therapeutics stock.
You can see the complete history of Johan Christenson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Johan Christenson biography
Dr. Johan Christenson M.D., Ph.D. serves as Independent Director of the Company. Dr. Christenson has been a Partner of HealthCap, a family of venture capital funds investing globally in life sciences. Previously, Dr. Christenson was with SEB Företagsinvest, another venture capital firm, to supervise its health care portfolio. He has senior management experience from Astra Pain Control as Project Director and AstraZeneca plc as Global Product Director and member of the global therapy area management team of pain and inflammation. Dr. Christenson received his medical training at the Karolinska Institute and received his Ph.D. in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in pediatrics and pediatric neurology. Dr. Christenson serves on the board of directors of Targovax AS (OSE: TRVX), InCarda Therapeutics, Inc. and Fusion Pharmaceuticals, Inc. He previously served on the boards of Algeta ASA (acquired by the Bayer Group), Oncopeptides AB and CoreValve, Inc. (acquired by Medronic, Inc.).
What is the salary of Johan Christenson?
As the Independent Director of Aprea Therapeutics, the total compensation of Johan Christenson at Aprea Therapeutics is $10,000. There are 9 executives at Aprea Therapeutics getting paid more, with Christian Schade having the highest compensation of $3,677,570.
How old is Johan Christenson?
Johan Christenson is 62, he's been the Independent Director of Aprea Therapeutics since 2016. There are 6 older and 11 younger executives at Aprea Therapeutics. The oldest executive at Aprea Therapeutics, Inc. is Guido Magni, 67, who is the Independent Director.
What's Johan Christenson's mailing address?
Johan's mailing address filed with the SEC is C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON, A6, L8P 0A6.
Insiders trading at Aprea Therapeutics
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... et John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
What does Aprea Therapeutics do?
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
What does Aprea Therapeutics's logo look like?
Complete history of Johan Christenson stock trades at Fusion Pharmaceuticals et Aprea Therapeutics
Aprea Therapeutics executives and stock owners
Aprea Therapeutics executives and other stock owners filed with the SEC include:
-
Christian Schade,
Chairman of the Board, President, Chief Executive Officer -
Scott Coiante,
Chief Financial Officer, Senior Vice President, Secretary -
Eyal Attar,
Senior Vice President, Chief Medical Officer -
Christian S. Schade,
Pres, CEO & Chairman -
Dr. Eyal C. Attar M.D.,
Sr. VP & Chief Medical Officer -
Scott M. Coiante,
Sr. VP, Company Sec. & CFO -
John Henneman,
Lead Independent Director -
Bernd Seizinger,
Independent Director -
Guido Magni,
Independent Director -
Johan Christenson,
Independent Director -
Dr. Oren Gilad Ph.D.,
Co-Founder, Pres & Director -
Richard Peters,
Director -
Fouad Namouni,
Director -
Michael Kelly,
Director -
Gregory Wessels,
Chief Commercial Officer -
Gregory Korbel,
Vice President - Business Development -
Lars Abrahmsen,
Senior Vice President, Chief Scientific Officer -
Andrea Epstein,
Controller -
Dr. Michel Afargan Ph.D.,
Head of Pharmacology Devel. -
Hank Breslin,
Head of Medicinal Chemistry -
Dr. Rifat Pamukcu M.D.,
Chief Medical Advisor & Director -
Dr. Dansu Li Ph.D.,
Head of Technology -
Dr. Lars B. Abrahmsen,
Sr. VP & Chief Scientific Officer -
Dr. Gregory A. Korbel Ph.D.,
Sr. VP & Chief Bus. Officer -
Ventures Iv, L.P.5 Am Co In...,
-
Marc Duey,
Director -
Michael Grissinger,
Director -
Rifat Pamukcu,
Director -
Ventures Iv, L.P.5 Am Co In...,
-
V Luxco S.A R.L.Versant Ven...,
-
Oren Gilad,
President, CEO -
Investments Ab Karolinska D...,
-
Scott M Rocklage,
Director -
V Luxco S.A R.L.Versant Ven...,
-
Vantage I, L.P.Versant Vant...,
-
Group, Llc Green Jeremy Red...,
-
Vii, L.P.Health Cap Vii Gp ...,
-
Jonathan Hepple,
-
John P. Hamill,
SrVP/CFO/Prin Fin & Acct Ofcr -
Gabriela Gruia,
Director -
Jean Pierre Bizzari,
Director -
Nadeem Q. Mirza,
Chief Medical Officer